Cory Hogaboam, Ph.D.
Associate Professor
Department of Pathology

hogaboam@umich.edu

Our research laboratory addresses two major themes related to chronic pulmonary disease. The first theme relates to cellular and molecular immune mechanisms that regulate the pulmonary growth and persistence of fungus in a number of experimental murine models. Specifically, we examine Aspergillus fumigatus , an ubiquitous fungal pathogen that initiates a broad spectrum of diseases ranging from lethal invasive growth to allergy and asthma. Our data to date has revealed that key immune cells such as myeloid cell progenitors, macrophages, and dendritic cells bridge the pulmonary innate and adaptive immune responses to this fungal pathogen. The second theme is more translational as we explore a grouping of clinical diseases referred to as idiopathic interstitial pneumonias (IIPs). IIPs are characterized by a lethal fibrotic response due to an exuberant fibroproliferative response by collagen producing cells in the lung. Using human tissues and isolated human cell populations, we are using large-scale genomic, proteomic and novel animal model approaches to explore the etiopathogenesis of these diseases, and, more importantly, identify novel therapeutic targets in IIPs.

Representative Publications

Carpenter K.J., Hogaboam C.M. Immunosuppressive effects of CCL17 on pulmonary anti-fungal responses during invasive pulmonary Aspergillosis. Infect. Immun., 73(11): 7198-7207, 2005.

Carpenter K.J., Buckland K.F., Xing Z., Hogaboam C.M. Intrapulmonary, adenovirus-mediated overexpression of KARAP/DAP-12 enhances fungal clearance during invasive Aspergillosis. Infect. Immun., 73(12): 8402-6, 2005.

Katano H., Hogaboam C.M. Herpes virus-associated pulmonary hypertension? Am. J. Respir. Crit. Care Med., 172(12): 1485-1486, 2005.

Denning D.W., O'Driscoll B.R., Hogaboam C.M., Bowyer P., Niven R.M. The link between fungi and asthma: a summary of the evidence. Eur. Respir. J., 27(3): 615-626, 2006.

Hartl D., Buckland K.F., Hogaboam C.M. Chemokines in allergic bronchopulmonary aspergillosis - from animal models to human lung diseases. Inflammation & Allergy – Drug Targets, 5(4): 219-228, 2006.

Buckland K.F., O'Connor E.C., Coleman E.M., Lira S.A. , Lukacs N.W., Hogaboam C.M. Remission of chronic fungal asthma in the absence of CCR8. J. Allergy Clin. Immunol., 119(4):997-1004. Feb 23, Epub ahead of print, 2007.

Pierce E.M., Carpenter K.J., Jakubzick C., Kunkel S.L., Flaherty K.R., Martinez F.J., Hogaboam C.M.   Idiopathic pulmonary fibrosis fibroblasts migrate and proliferate to CCL21.   Eur. Respir. J., 29(6): 1082-1093. March 1, Epub ahead of print, 2007.

Meneghin, A., Hogaboam, C.M. Infectious disease, the innate immune response, and fibrosis. J. Clin. Invest., 117(3): 503-508, 2007.

Wells, A., Hogaboam, C.M. Update in diffuse parenchymal lung disease 2006. Am. J. Respir. Crit. Care Med., 175(7): 655-660, 2007.

Pierce E.M., Carpenter K.J., Jakubzick C., Kunkel S.L., Flaherty K.R., Martinez F.J., Hogaboam C.M.   Therapeutic targeting of CCL21 or CCR7 abrogates pulmonary fibrosis induced by the adoptive transfer of human pulmonary fibroblasts into immunodeficient mice.   Am. J. Pathol., 170:1152-1164, 2007.